Zhi Tong Cai Jing·2026-03-06 12:21Core Viewpoint - Fosun International (00656) issued a profit warning, projecting a loss of approximately RMB 21.5 billion to RMB 23.5 billion for the fiscal year 2025, primarily due to one-time non-cash impairment charges and value reassessments, which do not affect overall operations and cash flow [1][2] Group 1: Financial Performance - The significant loss is attributed to the ongoing downturn in the real estate sector, leading to a soft market demand and pressure on the group's real estate business, prompting substantial asset impairment provisions [1] - The company plans to dynamically adjust its operational and sales strategies based on market conditions, aiming to enhance marketing efforts and accelerate cash recovery [1] - In the insurance sector, Fosun's Portuguese insurance reported a net profit of €170 million for the first three quarters of 2025, a year-on-year increase of 11.7%, while domestic insurance companies also reported considerable growth in premiums and net profits [3] Group 2: Strategic Focus - Fosun emphasizes its commitment to a "focus on core business" strategy and a "streamlining" financial strategy to promote business growth and solidify long-term value [1][3] - The company has engaged in significant partnerships in the innovative drug sector, including a global exclusive licensing agreement with Pfizer worth over $2 billion and a strategic collaboration with Clavis Bio potentially worth up to $7.25 billion [2] - The company is also increasing its share buyback efforts to instill market confidence, planning to repurchase shares up to HKD 1 billion following the 2025 annual performance announcement [4]